
## Modeling needs for gene drive mosquito projects


## **Gene Drive Research Forum 2024**



John Marshall
Divisions of Epidemiology & Biostatistics
School of Public Health
University of California, Berkeley
john.marshall@berkeley.edu



## Overview



Marshall JM, North AR (2023) Mosquito Gene Drives & Malaria Raban R, Marshall JM *et al.* (2023) Annual Review of Genetics

# Target product profiles

### **Model specification:**

### **Product parameters:**


- Homing rate
- Resistance generation rate
- Fecundity/mating cost of gene drive allele
- Fecundity/mating cost of resistance allele
- Efficacy of transmission blocking\*

### **Intervention parameters:**

- Number of mosquitoes per release
- Number of releases

### **Setting:**

- Initially, potential field sites
- Eventually, locations where gene drive may spread



#### **Outcomes of interest:**


- >20-50% reduction in prevalence
- >20-50% reduction in clinical incidence
- Impact within <6-12 months
- Duration of impact of >2-3 years

# Target product profile:

 Product & intervention parameters that satisfy outcomes of interest


Mondal A, Vásquez VN, Marshall JM (2021) Frontiers in Tropical Diseases

# Target product profiles for population replacement




Leung S, Windbichler N, Wenger EA, Bever CA et al. (2022) Malaria J

## TP13 population replacement construct



Carballar-Lejarazú R, Dong Y, Pham TB, Tushar T, Corder RM et al. (2023) PNAS

# Fitness-related parameters




Genotypes: HW HR


| D               | AcTP13 (An. coluzzii)      |                          |  |
|-----------------|----------------------------|--------------------------|--|
| Parameter       | Prior                      | Posterior                |  |
| $p_H^M$         | 97.8% (88.3% –<br>100%)    | 97.9% (82.5% -<br>99.9%) |  |
| $p_H^F$         | 98.4% (94.4% –<br>99.999%) | 98.5% (94.8% -<br>99.8%) |  |
| $p_B^F$         | N/A                        | N/A                      |  |
| мнн             | 1.04 (0.99 - 1.10)         | 1.05 (0.99 - 1.10)       |  |
| $m_H$           | 1.78 (1.60 - 1.96)         | 1.78 (1.60 - 1.96)       |  |
| $f_{HH}$        | -                          | 2.42 (0.85 - 3.67)       |  |
| f <sub>ri</sub> | -                          | 2.15 (1.24 - 3.82)       |  |

|                          |                   | GCIIC | rypc | 3. IIV | <b>v</b> ,                 | • |
|--------------------------|-------------------|-------|------|--------|----------------------------|---|
| ed or<br>eye             | 0:-               | _     |      | =      | Determi<br>Stochas<br>Data |   |
| CFP+ & red or mosaic eye | 0.5               |       |      |        |                            |   |
| GF m                     | o: - <del> </del> |       | -    |        |                            |   |
|                          | 0                 | 1     | 2    | 3      | 4                          | 5 |
|                          |                   | (     | Gene | ratio  | n                          |   |

• Carballar-Lejarazú R, Dong Y, Pham TB, Tushar T, Corder RM et al. (2023) PNAS


# Malaria transmission probability






- Aleshnick M, Ganusov VV, Nasir G, Yenokyan G et al. (2020) PLoS Pathogens
- Carballar-Lejarazú R, Dong Y, Pham TB, Tushar T, Corder RM et al. (2023) PNAS

## Environmental risk assessment






Connolly JB, Mumford JD, Fuchs S, Turner G, Beech C et al. (2021) Malaria Journal

# ERA modeling requires more ecological realism

| Type of stressor/ interaction         | EFSA 2013 characteristic   |                 | Implemented in GD models |                   |                       |       |  |  |
|---------------------------------------|--|-----------------|--------------------------|-------------------|-----------------------|-------|--|--|
|                                       |  | Other<br>models | North et al.             | Skeeter<br>Buster | MGDrivE               | SLiM3 |  |  |
| Abiotic factors                       | Temperature  | ✓               | /                        | 1                 | ×                     | ×     |  |  |
|                                       | Humidity   | ✓               | ✓                        | ✓                 | ×                     | ×     |  |  |
|                                       | Climatic/geographical barriers   | ✓               | 1                        | ✓                 | 1                     | 1     |  |  |
| Biotic characteristic                 | Distribution (before and after release)  | ✓               | ✓                        | ✓                 | ✓                     | ✓     |  |  |
| TO related                            | Fitness  | 1               | ✓                        | ✓                 | 1                     | 1     |  |  |
|                                       | Reproductive biology (fertility and fecundity) before and after release                                  | 1               | ✓                        | 1                 | ✓                     | 1     |  |  |
|                                       | Dispersal  | ✓               | ✓                        | ✓                 | ✓                     | ✓     |  |  |
|                                       | Population size, structure, sex ratio (before and after GM release)                                      | 1               | ✓                        | ✓                 | 1                     | ✓     |  |  |
|                                       | Reduction in efficiency/resistance development against GM  | ✓               | ×                        | ×                 | ✓                     | ✓     |  |  |
|                                       | Changes in interactions (behavioural, genetic) between GMO and TO  | ×               | ×                        | ×                 | ×                     | ×     |  |  |
| Interactions with other species (non- | Hybridization  | ×               | ×                        | ×                 | ×                     | ×     |  |  |
| target organisms)                     | Pathogens (altered transmission range and frequency), increased vector competence                        | ✓               | ×                        | ×                 | ✓                     | ×     |  |  |
|                                       | Adverse effects due to "low quality GM insects" e.g. increased human biting rate or disease transmission | ×               | ×                        | ×                 | ×                     | ×     |  |  |
|                                       | Prey   | ×               | ×                        | ×                 | ×                     | ×     |  |  |
|                                       | Predators/predation  | ×               | ×                        | ×                 | ×                     | ×     |  |  |
|                                       | Symbionts  | $\checkmark^5$  | ×                        | ×                 | <b>✓</b> <sup>5</sup> | ×     |  |  |
|                                       | Hosts (plants, animals)  | ×               | ×                        | ×                 | ✓                     | ×     |  |  |
|                                       | Parasites, pathogens   | ×               | ×                        | ×                 | ✓                     | ×     |  |  |
|                                       | Trophic level/food web effects   | ×               | ×                        | ×                 | ×                     | ×     |  |  |
|                                       | Competitors (abundance, species composition)   | ×               | ×                        | ×                 | ×                     | ×     |  |  |
|                                       | Ecosystem services   | ×               | ×                        | ×                 | ×                     | ×     |  |  |
|                                       | Toxins/allergens associated with GMO   | ×               | ×                        | ×                 | ×                     | ×     |  |  |


Frieß JL, Lalyer CR, Giese B, Simon S, Otto M (2023) Ecological Modelling


## Surveillance as a cost driver




Rašić G, Lobo NF, Jeffrey Gutiérrez EH, Sánchez C. HM, Marshall JM (2022) Frontiers in Genetics

# Optimal density & layout of traps






# Monitoring to infer fitness costs during a trial







- Hoffmann AA, Montgomery BL, Popovici J et al. (2011) Nature
- Carvalho DO, McKemey AR, Garziera L et al. (2015) PLoS Negl Trop Dis

# Field trial modeling: Wolbachia as a case study








Utarini A, Indiani C, Ahmad RA, Tantowiyojo W et al. (2021) New England J Medicine

# Field trial modeling: Spillover & TMLE



- Smith T, Multerer L, Silkey M (2024) <a href="https://cran.r-project.org/web/packages/CRTspat/">https://cran.r-project.org/web/packages/CRTspat/</a>
- van der Laan MJ, Rubin D (2006) Targeted Maximum Likelihood Learning

## Recap

## 1. Target product profiles:

- Determine when technology is ready for the field
- Some parameters can't be measured prior to release
- Parameter requirements may depend on others

#### 2. Risk assessment:


- A subset of identified risks are suited to modeling
- More ecological realism is needed


## 3. Monitoring & surveillance:


- Surveillance is expected to be a cost driver & requires efficient design
- Monitoring should infer fitness costs early in a trial

## 4. Field trial design:

- Wolbachia provides a case study, with differences
- Exploring new techniques to extract more power from field trial data







Distance to nearest discordant location 
Distance to nearest discordant location

## Acknowledgements

#### LAB MEMBERS:

- Héctor M. Sánchez C.
- o Rodrigo M. Corder
- Agastya Mondal
- Shuyi Yang
- Victor Mero
- Emma Lonstrup
- o Jared B. Bennett
- Váleri Vásquez
- o Sean L. Wu

- Yogita Sharma
- o Tomás León
- Sanjay Lamba
- o Francois Rerolle
- o Thien-An Ha
- Natasha Harrison
- Darpa Anireddy
- o Xingli Yu
- o Alan Hu

#### **COLLABORATORS:**

- Akbari Lab @ UCSD
- o James Lab @ UC Irvine
- o Bier Lab @ UCSD
- o **Dr Gordana Rašić** @ QIMR Berghofer
- o **Dr Samson Kiware** @ Ifakara Health Institute
- Environmental Health Institute @ NEA
- Dr David Smith @ IHME, UW
- School of Public Health @ UC Berkeley
- Malaria Elimination Initiative @ UCSF

### **FUNDERS:**

